Frances Valdes, MD

Dr C Ola Landgren, is a board-certified hematologist/oncologist who specializes in multiple myeloma, smoldering myeloma, monoclonal gammopathy of undetermined significance, and related plasma cell disorders. His research approaches include detailed genomic characterization of tumor cells and cells in the bone marrow microenvironment, partnered with novel drug development, and advanced methods to rule out minimal residual disease (MRD). Dr Landgren has developed several novel strategies designed to identify MRD detection post-therapy.